Oncology

The introduction of an electronic tracking system decreased the time from hepatocellular carcinoma (HCC) diagnosis to treatment by more than a month.

The global cancer immunotherapy market is set to grow at a compound annual growth rate, or CAGR, of 12.6% to $277.1 billion by 2030.

But the future of value-based care in oncology is uncertain with no certain successor to the Oncology Care Model in sight.

Reporting of PRO in oncology clinical trials increased after standards from ISOQOL and others were published in 2013.

Patients with a variety of cancers spent much more money out of their own pocket than those in traditional plans. Some may be delaying treatment due to higher costs.

Because of a COVID-19 related shortage, facilities may not have immediate access to Actemra, which is required as part of the REMS programs for CAR T-cell therapies.

Blood cancer patients who had at least some antibodies after the first two doses are likely to produce large amounts after the third vaccination.

Both Copiktra and Farydak had received accelerated approvals, and the FDA had required confirmatory trials. Secura Bio has determined such trials are not feasible.

The approval marks the ninth indication for Darzalex Faspro, the only subcutaneous anti-CD38 monoclonal antibody approved to treat multiple myeloma across multiple treatment regimens.

The warnings section of Inrebic, a JAK inhibitor to treat a bone marrow cancer, now includes information about the cardiovascular risk associated with Xeljanz, another JAK inhibitor to treat arthritis.

The regulatory agency has set a Prescription Drug User Fee Act date during the first quarter of 2022

Cytalux is the first imagining agent to illuminate ovarian cancer during surgery.

Keytruda is the first immunotherapy approved for treatment of patients with early renal cell carcinoma after surgery.

Most of the patients with no immune response after the two-dose regimen responded well to a third shot.

Site of service has a major effect on the cost. Home infusion and oral formulations are challenging both hospital- and physician-based infusions.

Patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma were more likely to have a COVID-19 breakthrough infection.

Per episode saving of $297 during the first three years of the value-based care model were offset by $704 in payments for enhanced services to the 201 participating practices, study finds.

The studies conducted to support Verzenio’s most recent approval for the treatment of high-risk early breast cancer provided additional safety data.

The agency needs more time to review new information on the analytical method used.

Several generics of the cancer therapeutic are available.

Novartis’ Scemblix was approved for previously treated patients and for those who are resistant to TKI inhibitors.

Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.

Cumulative spending on drugs without overall survival data was $1.8 billion in 2018 and surpassed that of drugs with such data.

Oncopeptides will close down its business units in the United States and Europe to focus exclusively on being a Sweden-based R&D company.

If a patient does not remain on the drug for at least three months due to effectiveness or tolerability, a significant portion of the drug cost will be refunded to Point32Health.

Tecentriq is the first cancer immunotherapy available for adjuvant treatment of non-small cell lung cancer (NSCLC).

Dr. Reddy’s received FDA approval for two strengths of lenalidomide for the treatment of patients with multiple myeloma.

Narsoplimab was under review at the FDA to treat a complication of stem cell transplants.

In COVID-19 news: An advisory committee recommends both J&J's and Moderna’s booster, Regeneron seeks full approved for its treatment and Merck seeks EUA for treatment. In cancer, the FDA approves Verzenio for early breast cancer, Keytruda for advanced cervical cancer, and Tecentriq in early nonsmall cell lung cancer.

This is the first anti-PD-1 combination approved for patients with persistent, recurrent or metastatic cervical cancer.